MedPath

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

Phase 3
Completed
Conditions
Glabellar Lines
Lateral Canthal Lines
Interventions
Biological: botulinum toxin neuromodulator
Registration Number
NCT04225260
Lead Sponsor
Galderma R&D
Brief Summary

This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
902
Inclusion Criteria
  • Male or female at least 18 years of age.
Exclusion Criteria
  • Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.
  • Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than the investigational product).
  • Female who is pregnant, breast feeding, or intends to conceive a child during the study.
  • Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
QM1114-DP in the LCL and the GL areasbotulinum toxin neuromodulatorThe investigational product (QM1114-DP) is a BoNT Type A. At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines.
Primary Outcome Measures
NameTimeMethod
Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum FrownWeek 4

4-point scale

Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum SmileWeek 4

4-point scale

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (30)

Skin Laser and Surgery Specialist of NY/NJ

🇺🇸

Hackensack, New Jersey, United States

Center for Clinical and Cosmetic Research

🇺🇸

Aventura, Florida, United States

Steven Fagien, MD, PA

🇺🇸

Boca Raton, Florida, United States

Research Institute of SouthEast, LLC

🇺🇸

West Palm Beach, Florida, United States

Aventiv Research, Inc.

🇺🇸

Dublin, Ohio, United States

Center for Advanced Clinical Research

🇺🇸

Dallas, Texas, United States

Chicago Cosmetic Surgery and Dermatology, Inc

🇺🇸

Chicago, Illinois, United States

Investigate MD, LLC.

🇺🇸

Scottsdale, Arizona, United States

Total Skin and Beauty Dermatology Center, PC

🇺🇸

Birmingham, Alabama, United States

Elite Aesthetic Research

🇺🇸

Cincinnati, Ohio, United States

The Maas Clinic Research Center

🇺🇸

San Francisco, California, United States

Rejuva Medical Aesthetics, LLC

🇺🇸

Los Angeles, California, United States

Westside Aesthetics

🇺🇸

Los Angeles, California, United States

Center for Dermatology Clinical Research, Inc.

🇺🇸

Fremont, California, United States

Marcus Facial Plastic Surgery

🇺🇸

Redondo Beach, California, United States

ArteMedica

🇺🇸

Santa Rosa, California, United States

AboutSkin Research, LLC

🇺🇸

Greenwood Village, Colorado, United States

Modern Dermatology PC

🇺🇸

Westport, Connecticut, United States

Susan H. Weinkle, M.D

🇺🇸

Bradenton, Florida, United States

Miami Skin and Vein LLC

🇺🇸

Coral Gables, Florida, United States

Mayoral Dermatology

🇺🇸

Coral Gables, Florida, United States

Skin Research Institute, LLC

🇺🇸

Coral Gables, Florida, United States

Hamilton Research LLC

🇺🇸

Alpharetta, Georgia, United States

Pure Dermatology, LLC

🇺🇸

Metairie, Louisiana, United States

SkinCare Physicians

🇺🇸

Chestnut Hill, Massachusetts, United States

Austin Institute for Clinical Research, Inc.

🇺🇸

Pflugerville, Texas, United States

Dallas Plastic Surgery Institute

🇺🇸

Dallas, Texas, United States

SkinDC, PLLC

🇺🇸

Arlington, Virginia, United States

EthiQ2 Research, LLC

🇺🇸

Mequon, Wisconsin, United States

Jose Raul Montes Eyes & Facial Rejuvenation LLC

🇵🇷

San Juan, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath